At baseline ( 9.5 vs. 14.4 mcg/mL ) and during follow-up [ 7.5 ( 4.4-9 .8 ) vs. 13.9 ( 8.9-23 .6 ) mcg/mL , p < 0.01 ] , median adalimumab trough levels in patients with clinical or endoscopic recurrence were lower than in those who maintained remission .